Research and Clinical Trials

Brief Description  
With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem. The purpose of this study is to evaluate the safety of a new medication (GSK1349572) in HIV infected individuals who are currently prescribed an antiretroviral (ARV) regimen that has failed. This study is also comparing the efficacy of GSK1349572 to Raltegravir which is an FDA approved integrase inhibitor used for HIV therapy.
Who may be Eligible  

You may be eligible if you:
  1. Are an HIV infected individual who is 18 years old or older
  2. Have failed a ARV regimen.
  3. Have a viral load >400 copies/mL
  4. You are not pregnant or breastfeeding or planning on becoming pregnant during the term of the trial (48 weeks).
  5. Have resistance to at least two classes of HIV medication
  6. Have never taken a medication from the Integrase category of HIV medications
  7. Have no active AIDS defining illness at your first study visit.
  8. Have not received an HIV-1 vaccine in the past 90 days
  9. Do not meet criteria of exclusion based on your routine lab results
  10. Do not have a history of cancer in the past 5 years
  11. Will not be treated for hepatitis C during the study term.
  12. Have not received an experimental medication within 28 days
IRB Number  
Principal Investigator  
Johnson, Marc

For More Information, Contact  Jessica  A, Kearney-Bryan
Phone:  (704) 355-0244  Fax:  (704) 446-7641  
Address:3rd Floor Myers Park Clinic 1350 South King's Drive Charlotte, NC 28207